{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:08:23Z","timestamp":1778623703316,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU23-07-00079"],"award-info":[{"award-number":["NU23-07-00079"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T07:13:39Z","timestamp":1726298019000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-8714","authenticated-orcid":false,"given":"Ondrej","family":"Cinek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6318-6645","authenticated-orcid":false,"given":"Eva","family":"Furstova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stepanka","family":"Novotna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Hubackova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-5035","authenticated-orcid":false,"given":"Tereza","family":"Dousova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Borek-Dohalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-5240","authenticated-orcid":false,"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.09.005_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.005_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.005_bib0005","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2024.09.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00156-2024","article-title":"Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay","volume":"63","author":"Furstova","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.005_bib0007","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2021.07.006","article-title":"Response to elexacaftor\/tezacaftor\/ivacaftor in intestinal organoids derived from people with cystic fibrosis","volume":"21","author":"Furstova","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009548","article-title":"The influence of genetics on cystic fibrosis phenotypes","volume":"2","author":"Knowles","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jcf.2024.09.005_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biocel.2014.02.011","article-title":"Lung disease modifier genes in cystic fibrosis","volume":"52","author":"Guillot","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jcf.2024.09.005_bib0010","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.1038\/ncomms9382","article-title":"Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis","volume":"6","author":"Corvol","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2024.09.005_bib0011","doi-asserted-by":"crossref","first-page":"562s","DOI":"10.3390\/genes12040562","article-title":"Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine","volume":"12","author":"Sepahzad","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcf.2024.09.005_bib0012","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.202209-1653OC","article-title":"Genetic modifiers of cystic fibrosis lung disease severity: whole-genome analysis of 7,840 patients","volume":"207","author":"Zhou","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.09.005_bib0013","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jcf.2020.04.005","article-title":"Global assessment of the integrated stress response in CF patient-derived airway and intestinal tissues","volume":"19","author":"Bampi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.005_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway epithelial inflammation in vitro augments the rescue of mutant CFTR by Current CFTR modulator therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.09.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00746-2023","article-title":"Cystic fibrosis airway inflammation enables elexacaftor\/tezacaftor\/ivacaftor-mediated rescue of N1303K CFTR mutation","volume":"10","author":"Gentzsch","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2024.09.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of CFTR function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis","author":"Loske","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:15:13Z","timestamp":1778620513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017132"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}